MediciNova, Inc. (MNOV) Receives Notice of European Patent Allowance for MS drug
From The QualityStocks Daily Blog for Micro-cap and Small-Cap Companies
November 26, 2012 - 7:28am
MediciNova received a notice of allowance from the European Patent Office for a pending patent application which covers the use of ibudilast (MN-166) for the treatment of progressive forms of multiple sclerosis (MS). MN-166 is the company’s drug development candidate for certain neurological conditions, including progressive MS, drug addiction, and pain. Patents maturing in this [...]
Continue reading this article »Share This Article: